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45 Co-existence of alcohol use and metabolic risk – the two commonest population risk factors for 
46 non-viral chronic liver disease – is a growing concern. Clinical and mechanistic evidence point to 
47 considerable supra-additive interaction effects for the development and progression of chronic 
48 liver disease between hazardous alcohol use and metabolic abnormalities including obesity, 
49 diabetes, and the metabolic syndrome. Intermittent binge drinking once monthly or more often 
50 seems to be associated with progression of liver disease even when average alcohol intake is 
51 within the currently allowed limits for a diagnosis of non-alcoholic fatty liver disease (NAFLD), 
52 and supra-additive interaction between binge drinking and the metabolic syndrome has been 
53 reported. There are contradictory findings regarding the association between low alcohol use and 
54 liver steatosis, but, clearly, the mechanisms of alcoholic hepatotoxicity extend beyond simple fat 
55 accumulation. The presence of liver steatosis seems to amplify alcoholic hepatotoxicity. Recent 
56 longitudinal studies of NAFLD subjects report low alcohol use associated with both increased 
57 fibrosis progression and an elevated risk for liver cancer and severe liver disease. There is no clear 
58 safe limit of alcohol intake in the presence of NAFLD or metabolic risk. The interaction effects 
59 between alcohol and metabolic dysfunction merit increased attention in public health policy, 
60 individual counseling, and risk stratification. Based on current evidence, a strict dichotomization 
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62 Introduction
63 Chronic liver disease and its complications is a growing global public health burden. Worldwide, 
64 liver cirrhosis is the 11th leading cause of death, and hepatocellular carcinoma is the 4th leading 
65 cause of cancer death (Asrani et al., 2019). 
66
67 Alcohol use and obesity and associated metabolic abnormalities are key independent population 
68 risk factors for non-viral liver cirrhosis, hepatocellular carcinoma (HCC), and for prognosis in 
69 established liver disease (Stepanova et al., 2010). 
70
71 At the population level, there is an exponential dose-response relationship between alcohol 
72 consumption and the risk for liver cirrhosis (Rehm et al., 2010; Thun et al., 1997; Askgaard et al., 
73 2015; Bellentani et al., 2000; Hagstrom et al., 2018). Both in general contexts (WHO, 2018) and in 
74 liver-specific contexts (European Association for the Study of the Liver, 2016; Chalasani et al., 
75 2018), hazardous alcohol use is currently considered as a regular intake of more than 20 grams of 
76 pure alcohol per day for women (140g/wk) or 30 grams for men (210g/wk), and these same 
77 cutoffs have been used to separate alcoholic liver disease from non-alcoholic fatty liver disease 
78 (NAFLD). However, the risk for liver cirrhosis begins to increase at alcohol consumption around 
79 12-24 grams of alcohol per day or even lower, and no liver-safe limit of alcohol intake has been 
80 firmly established (Roerecke et al., 2019; Rehm et al., 2010). Individual susceptibility to liver 
81 toxicity from alcohol is wide and seems to depend on drinking pattern (binge drinking, drinking 
82 outside meals), beverage type (lower risk for wine), gender, genetic and environmental factors, 
83 diet, gut microbiome and co-morbidity. 
84
85 Obesity, especially abdominal obesity, is associated with metabolic abnormalities and NAFLD 
86 (Liu et al., 2010; Harris et al., 2017; Hagstrom et al., 2018; Caballeria et al., 2018) and is also a 
87 co-factor in other types of liver diseases including alcoholic liver disease (Åberg et al., 2019; 
88 Diehl and Day, 2017). NAFLD affects an estimated 25% of individuals in the general population, 
89 and over 90% of those severely obese (Younossi et al., 2016), but less than 5% of NAFLD patients 
90 eventually develop end-stage liver disease.
91
92 There is considerable overlap in the molecular pathways between alcoholic and non-alcoholic liver 
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94 studies have suggested synergism between the hepatotoxic effects of alcohol and high-fat diet-
95 induced obesity (Minato et al., 2014; Xu et al., 2011; Duly et al., 2015).
96
97 Currently around 23% of adults are obese, rising to 38% in the USA (OECD, 2017). Similarly, an 
98 estimated quarter of the world’s population suffers from the metabolic syndrome (MetS) (O'Neill 
99 and O'Driscoll, 2015). Alcohol consumption in the population varies by region, but around 60% of 
100 adults in Europe and the USA drink alcohol. When abstainers are excluded, average annual 
101 consumption per capita among the actively drinking population is 15-17 litres of pure alcohol per 
102 year (WHO, 2018). Therefore, many persons with obesity and/or metabolic disorders also 
103 consume significant amounts of alcohol, and the synergistic interaction between them can 
104 potentially have enormous impact on the population incidence of liver disease. In support of this, 
105 we recently showed that 40% of cases of advanced non-viral liver disease in the general 
106 population occurs in individuals with co-existent metabolic risk and regular alcohol intake, but 
107 with a risk profile that does not fit either pure NAFLD or pure alcoholic liver disease (Åberg et al., 
108 2019b).
109
110 On the other hand, light alcohol consumption has been associated with improved insulin 
111 sensitivity and lipid profile, inhibition of platelet activation, reduction of fibrinogen level, and 
112 anti-inflammatory effects (Davies et al., 2002; Sierksma et al., 2004) possibly mediated through 
113 phenol and polyphenol content in wine and beer (Gresele et al., 2011). This is substantiated by 
114 some studies suggesting an association between low alcohol use and reduced prevalence of hepatic 
115 steatosis (Gunji et al., 2009; Yamada et al., 2010; Moriya et al., 2011; Hiramine et al., 2011; 
116 Hamaguchi et al., 2012; Dunn et al., 2012; Mitchell et al., 2018; Sookoian et al., 2014; Moriya et 
117 al., 2015; Kwon et al., 2014; Hagstrom et al., 2017), but the evidence is conflicting and suffers 
118 from methodological weaknesses. The recent Global Burden of Disease study concluded that the 
119 level of alcohol consumption that minimizes health loss is zero (GBD 2016 Alcohol Collaborators, 
120 2018).
121
122 The purpose of this critical review is to discuss the following aspects based on recently published 
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124 1) Does the combined effects of hazardous alcohol use and metabolic disorders increase the risk 
125 for liver disease over and beyond the sum of their individual effects (supra-additive/synergistic 
126 interaction) (Figure 1)?
127 2) Is there a safe, or even beneficial, level of alcohol use in persons with NAFLD or metabolic 
128 dysfunction (Figure 1)?
129
130 Methods
131 For the purpose of this review, we conducted a search of the PubMed database and applied citation 
132 chaining. For the first part, we included studies reporting interactions between hazardous alcohol 
133 use (>200g/wk) and obesity or other metabolic factors for liver outcomes. As hazardous alcohol 
134 intake usually represented the highest drinking category in these studies, we used the highest 
135 drinking category when evaluating interaction effects. Regarding obesity, we concentrated on 
136 body-mass index (BMI) ≥30kg/m2 if this was reported. If alternative anthropometric measures 
137 were reported, we also included these. From the relative risk estimates reported in the article, we 
138 calculated attributable proportion due to interaction (Figure 1) according to Rothman (Rothman, 
139 2002). For the second part (low alcohol use), we focused on studies analyzing clinically 
140 meaningful liver outcomes (fibrosis, steatohepatitis, or clinical endpoints) in the presence of 
141 baseline hepatic steatosis or metabolic risk. We relied on the definition of NAFLD used in the 
142 various studies, which usually involved consumption below 20 grams of pure alcohol per day for 
143 women and below 30 grams per day for men.
144
145 Interactions between hazardous alcohol use and obesity in clinical studies
146 We found 15 studies analyzing interactions between obesity and alcohol use for liver outcomes; 8 
147 were cross-sectional (1 case-control) and 7 longitudinal (Table 1). The longitudinal studies all 
148 used cohort methods and were mostly based on various population surveys, thus considered fairly 
149 representative of the general population.
150
151 All studies analyzed obesity by BMI (Table 1). Only one study considered waist circumference in 
152 addition to BMI (Åberg et al., 2018). BMI <25 kg/m2 was used as the reference group in 
153 interaction analyses in 8 of 15 studies; 3 studies used BMI <30 kg/m2 as reference, one study used 
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155 compared to a reference group. Four studies explicitly stated to exclude underweight subjects from 
156 the reference group. In interaction analyses, obesity was most often defined by a BMI ≥30 kg/m2. 
157
158 There was wide variation among studies in categorization of alcohol intake, both with regard to 
159 the reference group and the highest consumption category (Table 1). Only 2 studies analyzed sex-
160 specific limits for alcohol intake (Åberg et al., 2018; Lau et al., 2015), and only 1 study explicitly 
161 also analyzed binge drinking (Lau et al., 2015).
162
163 The outcome considered was abnormal liver enzymes in 5 studies, ultrasound-diagnosed steatosis 
164 in 3, HCC in 3, liver mortality in 1, and a composite endpoint of liver-related hospital admission, 
165 mortality (and HCC) in 3.
166
167 Supra-additive interaction between obesity and alcohol use was seen in 4 of 5 studies analyzing 
168 liver enzymes (especially for gamma-glutamyltransferase (GGT)), and in 1 of 3 studies analyzing 
169 steatosis. It should be noted that an elevated GGT may also reflect hazardous alcohol use without 
170 liver injury (Niemelä and Alatalo, 2010). Of the 7 studies analyzing clinical liver outcomes, 5 
171 found considerable supra-additive harmful effects between alcohol use and BMI, and additionally 
172 1 study found such effects for waist circumference but not for BMI (Åberg et al., 2018). These 
173 studies showing interaction were from England, Scotland, Finland and Taiwan. In contrast, Yi et al 
174 (Yi et al., 2016) reported the highest risk of death from non-neoplastic liver disease in 
175 underweight hazardous drinkers, and found no supra-additive interaction between obesity and 
176 alcohol use compared to subjects with a BMI 25-27.4 kg/m2 and alcohol use <9 g/wk. This South-
177 Korean study was restricted to men, relied on self-reported weights, defined obesity as a BMI 
178 ≥27.5 kg/m2, and excluded liver cancer mortality from the outcome (Yi et al., 2016). The lower 
179 limit of alcohol intake in the highest drinking category was also relatively low (126 g/wk, based 
180 on the study’s definition of a standard drink).
181
182 In studies reporting supra-additive interaction, the fraction of risk attributable to interaction 
183 between drinking and obesity varied between 26-88% for elevated liver enzymes, and between 25-
184 67% for clinical liver outcomes (Table 1). Lau et al (Lau et al., 2015) also reported supra-additive 
185 interaction between obesity and binge drinking (at least 5 drinks per day at least 1 time during the 
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187
188 Interaction between hazardous alcohol use and other metabolic factors
189 The association between obesity and liver disease is considered to be driven largely by associated 
190 metabolic abnormalities, primarily insulin resistance (Gutierrez-Grobe et al., 2017; Ampuero et 
191 al., 2018).
192
193 We found 5 studies (1 cross-sectional, 2 case-control and 2 longitudinal) that analyzed interactions 
194 for liver-disease risk between alcohol and other metabolic factors than obesity; 3 analyzed 
195 diabetes and 2 analyzed metabolic syndrome (Table 2). There was a profound interaction effect 
196 between hazardous drinking and diabetes for the liver risk in all 3 studies, with estimates of 
197 proportion attributable to interaction around 60-74% (Table 2). Park et al (Park et al., 2013) 
198 reported supra-additive interaction between hazardous drinking and the metabolic syndrome for 
199 GGT and aspartate aminotransferase (AST) elevation, and non-significantly so for alanine 
200 aminotransferase (ALT). In our longitudinal population study (Åberg et al., 2017), we found a 
201 supra-additive interaction effect between weekly binge drinking and presence of the MetS for 
202 clinical liver outcomes (hospital admission, liver cancer or liver death) when adjusted for age and 
203 average alcohol use (Figure 2). 
204
205 In addition to these studies, Younossi et al (Younossi et al., 2019) reported supra-additive 
206 interaction between hazardous alcohol use and the MetS for all-cause death in subjects with 
207 baseline liver steatosis, based on the NHANES III survey. However, they found that the 
208 interaction term between binge drinking and MetS was non-significant for all-cause death in these 
209 subjects.
210
211 Low alcohol intake in the presence of NAFLD and/or metabolic risk
212 There are no randomized trials evaluating the effects of low alcohol intake in patients with 
213 NAFLD. Several observational studies link light-moderate alcohol use, as compared to abstinence, 
214 with a reduced risk for liver steatosis (Dunn et al., 2012; Mitchell et al., 2018; Sookoian et al., 
215 2014; Kwon et al., 2014; Hagstrom et al., 2017; Dixon et al., 2001). However, recent reviews 
216 (Ajmera et al., 2017; Boyle et al., 2018) have raised several important methodological concerns 
217 with these studies, including incomplete adjustment for confounders such as physical activity, 
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219 sectional and use surrogate endpoints such as steatosis or liver enzymes (Gunji et al., 2009; 
220 Yamada et al., 2010; Moriya et al., 2011; Hiramine et al., 2011; Hamaguchi et al., 2012; Sookoian 
221 et al., 2014; Moriya et al., 2015). The majority of these studies come from Japan, and ethnicity 
222 may influence alcohol metabolism and thereby modify alcoholic liver toxicity (Kourkoumpetis 
223 and Sood, 2019). In fact, the findings in the Japanese studies are in sharp contrast with those in 
224 some similar Western studies (Lau et al., 2015; Ruhl and Everhart, 2005; Suomela et al., 2015; 
225 Alatalo et al., 2008), and in contrast with longitudinal general population-based studies reporting 
226 increased risk for severe liver disease at alcohol intake even lower than 2 drinks/day (Rehm et al., 
227 2010; Askgaard et al., 2015; Hagstrom et al., 2018; Åberg et al., 2018; Simpson et al., 2019; 
228 Sahlman et al., 2019). Simple liver steatosis or elevated liver enzymes may be poor outcome 
229 measures in population studies due to unclear prognostic relevance. We focus this part of our 
230 review on studies analyzing defined endpoints with acknowledged clinical relevance 
231 (steatohepatitis, fibrosis, or symptomatic liver disease), specifically in populations with NAFLD or 
232 metabolic risk. We found 17 such studies (10 cross-sectional, 7 longitudinal), summarized in 
233 Table 3.
234
235 Of 10 cross-sectional studies, 9 were based on selected patient populations from hospital clinics 
236 with biopsy-confirmed NAFLD or obese subjects undergoing bariatric surgery (Table 3). The 
237 population-based studies instead defined steatosis using ultrasound or specific indices (fatty liver 
238 index, hepatic steatosis index). The upper limit for low alcohol intake in these studies was 
239 typically set at ~20-30 g/day depending on the study. 
240
241 Six studies stated explicitly how they treated former drinkers (current abstainers with previous 
242 drinking) (Dunn et al., 2012; Kwon et al., 2014; Dixon et al., 2001; Åberg et al., 2019a; Ascha et 
243 al., 2010; Ajmera et al., 2018), 6 stated how they treated binge drinkers (Dunn et al., 2012; 
244 Mitchell et al., 2018; Younossi et al., 2019; Åberg et al., 2019a; Ajmera et al., 2018; Ekstedt et al., 
245 2009) and 5 evaluated lifetime drinking in their analyses (Dunn et al., 2012; Mitchell et al., 2018; 
246 Kwon et al., 2014; Hagstrom et al., 2017; Ajmera et al., 2018). Two studies had repeated 
247 measurements of alcohol use over time (Ajmera et al., 2018; Ekstedt et al., 2009), although these 
248 findings were not explicitly reported. There was a wide variation in the factors adjusted for in 
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251 In cross-sectional clinical studies with liver histology, 2 (Dixon et al., 2001; Cotrim et al., 2009) 
252 reported no independent effect of low alcohol intake on liver-disease severity, whereas 5 (Dunn et 
253 al., 2012; Mitchell et al., 2018; Sookoian et al., 2014; Kwon et al., 2014; Hagstrom et al., 2017) 
254 reported less severe liver disease with low alcohol intake compared to abstinence. Dietary factors 
255 were poorly adjusted for in these studies. 
256
257 Dunn et al (Dunn et al., 2012) reported lower odds of steatohepatitis (OR 0.56) and fibrosis (OR 
258 0.56) among modest drinkers compared to lifetime abstainers. This study was based on patients 
259 referred to specialized clinics participating in the NASH Clinical Research Network. Mitchell et al 
260 (Mitchell et al., 2018) found less liver fibrosis in exclusive light wine drinkers, but not in 
261 exclusive beer drinkers, compared to lifetime abstinent subjects. The association with reduced 
262 liver fibrosis was not seen in subjects reporting binge drinking.
263
264 Furthermore, Hagström et al (Hagstrom et al., 2017) also found less liver fibrosis among those 
265 reporting low alcohol consumption, but, somewhat paradoxically, they found an association 
266 between elevated alcohol markers (phosphatidylethanol) and more liver fibrosis.
267
268 Wong et al (Wong et al., 2012) evaluated a population-based cohort of 922 subjects from Hong 
269 Kong for liver steatosis and fibrosis by magnetic resonance spectroscopy and transient 
270 elastography, respectively, and reported a weak direct correlation between alcohol use and 
271 prevalent steatosis (non-significant in multivariate analysis), but no association with liver fibrosis. 
272
273 In a recent longitudinal study with paired liver biopsies of NAFLD patients, Ajmera et al (Ajmera 
274 et al., 2018) found low alcohol use (≤2 drinks/day) associated with lower odds of NASH 
275 resolution compared with abstinence (OR 0.32) on adjusted analysis, and the drinkers exhibited 
276 less reduction over time in steatosis grade and AST level. The study excluded former drinkers 
277 from the abstinent group. These data provide strong evidence for liver harm from low alcohol use, 
278 strongly challenging the cross-sectional studies above, although partly based on the same patients 
279 (Dunn et al., 2012). 
280
281 Ekstedt et al (Ekstedt et al., 2009) found binge drinking at least once monthly associated with 
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283
284 A recent Mendelian randomization study categorized patients with NAFLD based on their 
285 aldehyde dehydrogenase genotype to those prone to consume more or less alcohol (Sookoian et 
286 al., 2016). The NAFLD patients genetically prone to drink less alcohol had less hepatic steatosis 
287 and less features of steatohepatitis on histology compared to those prone to drink more alcohol, 
288 which again suggests harmful effects of alcohol use in NAFLD.
289
290 In a large longitudinal Korean population cohort of 58 927 individuals with ultrasound-based 
291 steatosis, Chang et al (Chang et al., 2019) found light to moderate alcohol intake associated with a 
292 worsening of liver fibrosis over time based on non-invasive fibrosis markers. However, although 
293 suitable for ruling out advanced fibrosis, these non-invasive fibrosis markers have a low positive 
294 predictive value for fibrosis, and have not been validated for assessing change in fibrosis over 
295 time. Age is a component in the scores used, and a rising score is thus, in part, a consequence of 
296 aging itself. It therefore remains unclear whether the worsening in the fibrosis scores over time 
297 truly reflect fibrosis progression.
298
299 Another longitudinal Japanese study of NAFLD patients from a specialized hepatology center 
300 found increased HCC risk with increasing alcohol use, becoming significant at ≥40 g/day 
301 (Kawamura et al., 2016).
302
303 We recently reported the findings from a large cohort study of 8345 individuals with hepatic 
304 steatosis (fatty liver index >60) from the Finnish general population with linkage to nationwide 
305 reliable registries for hard clinical endpoints (hospital admission, cancer, or death related to 
306 advanced liver disease), and with adjustment for multiple acknowledged confounders and with 
307 exclusion of former drinkers (Åberg et al., 2019a). In this study, the presence of steatosis at 
308 baseline amplified the dose-dependent risk relationship between alcohol and incident liver disease. 
309 Among subjects with baseline steatosis, we found no benefits from low alcohol intake with 
310 regards to the risk for incident advanced clinical liver disease (Åberg et al., 2019a). Consuming 
311 more than 10 g/day of alcohol increased the risk for liver disease in a dose-dependent fashion 
312 regardless of the level of adjustment for confounders. One drink per day of non-wine beverages, or 
313 2 drinks per day as wine, doubled the risk for advanced liver disease compared to lifetime 
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315
316 Extending these findings, among obese men in the general population with a waist-hip ratio in the 
317 highest tertile, 1 daily alcohol drink yielded a similar relative risk for incident liver disease as 4 
318 daily drinks in non-obese men (Figure 3) (Sahlman et al., 2019). This means that, in the presence 
319 of marked abdominal obesity, hepatic toxicity of alcohol increases by a number of four.
320
321 Vilar-Gomez et al (Vilar-Gomez et al., 2018) found that, in patients with NAFLD-cirrhosis, low 
322 alcohol use (<30 g/day for men and <20g/d for women) was associated with an increased risk of 
323 death or liver transplantation (hazards ratio 2.3), hepatic decompensation (hazards ratio 1.7), and 
324 HCC (hazards ratio 3.2) compared to abstinence, a finding that reinforces the need for absolute 
325 alcohol abstinence in patients with cirrhosis. Two additional studies found an increased risk for 
326 HCC among NAFLD patients with advanced fibrosis or cirrhosis reporting any alcohol use (Ascha 
327 et al., 2010; Kimura et al., 2018).
328
329 Extra-hepatic outcomes in NAFLD
330 A J-shaped cardiovascular- and mortality benefit from low alcohol use in the general population is 
331 widely reported (Di Castelnuovo et al., 2006), but has recently been questioned by the findings 
332 from a robust meta-analysis (Wood et al., 2018).
333
334 A recent study in NAFLD patients with prospectively assessed alcohol consumption over time 
335 found no association between low alcohol use and the presence of cardiovascular risk factors or 
336 subclinical cardiovascular disease (VanWagner et al., 2017). 
337
338 There are conflicting data regarding a J-shaped relationship between low alcohol use and all-cause 
339 death in NAFLD cohorts in recent population-based studies (Younossi et al., 2019; Åberg et al., 
340 2019a; Hajifathalian et al., 2019). In our longitudinal population study, such a J-shaped 
341 association between low alcohol use and all-cause death was only seen among never smokers, not 
342 among current or former smokers (Åberg et al., 2019a). Alcohol intake more than 30 g/day was 
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345 Even low alcohol intake is associated with an increased risk for several types of cancer both in the 
346 general population (Cao et al., 2015; Bagnardi et al., 2013) and in individuals with NAFLD 




351 Interaction between hazardous alcohol use and metabolic risk
352 The majority of studies report significant supra-additive interaction between hazardous alcohol use 
353 and obesity for various liver outcomes including clinical ones (hospital admission due to liver 
354 disease, liver cancer and liver-related death). Based on longitudinal studies with clinical liver 
355 endpoints, approximately 50% of the excess risk for liver disease from the combination of 
356 hazardous alcohol use and obesity is due to their interaction effects, whereas the remaining 50% is 
357 due to the independent effects of alcohol and obesity. However, there was considerable variation 
358 by study to the interaction estimate (range 0-67%), largely explained by methodological 
359 differences. Alcohol, metabolic factors and their interactions may also affect the various liver 
360 outcomes differently.
361
362 The synergistic interactions observed in these epidemiological studies are well in line with 
363 mechanistic studies showing hepatotoxic effects from the combined exposure to alcohol and high-
364 fat diet above and beyond the sum of their individual effects (Minato et al., 2014; Xu et al., 2011; 
365 Duly et al., 2015).
366
367 A number of caveats merit consideration when interpreting the epidemiologic findings. Many 
368 studies failed to exclude former heavy drinkers from the reference group. Former drinkers may be 
369 enriched with more co-morbidity and other factors affecting the choice to abstain from alcohol but 
370 simultaneously raising the risk for liver disease (sick quitter bias). This may attenuate the observed 
371 harm from alcohol in epidemiological studies. 
372
373 Similarly, there seems to be a U-shaped association between BMI and incident liver outcomes 
374 (Liu et al., 2010), where underweight might reflect liver disease or other form of illness. In 
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376 reflect the person’s usual weight. Prospective population cohort studies have an advantage in this 
377 regard as BMI will generally reflect a healthy weight.
378
379 None of the longitudinal studies with clinical endpoints seems to have excluded both underweight 
380 subjects and previous heavy drinkers from the reference group. If one were to apply these 
381 exclusion criteria, the synergistic interaction would expectedly be even more pronounced.
382
383 BMI is an imperfect index for obesity when assessing risk for liver disease. Measures that better 
384 reflect abdominal, also called visceral or central, adiposity, such as waist circumference and waist-
385 hip ratio (WHR), seem superior to BMI in predicting incident liver disease (Åberg et al., 2018; 
386 Pang et al., 2015; Andreasson et al., 2017; Ioannou et al., 2005). The supra-additive interaction 
387 effect also seems to become stronger when obesity is measured by the WHR (Sahlman et al., 
388 2019) or waist circumference (Åberg et al., 2018).
389
390 Binge drinking
391 Binge drinking, or heavy episodic drinking, is generally defined as drinking 60 gram alcohol or 
392 more on one occasion at least once during the last month (WHO, 2018). Binge drinking has a 
393 number of potentially harmful effects on the liver (Llerena et al., 2015), and has, for example, 
394 been shown to induce insulin resistance that lasts even after blood alcohol levels become 
395 undetectable (Lindtner et al., 2013). This contrasts to the improved insulin sensitivity associated 
396 with low alcohol use. 
397
398 Binge drinking habits may be neglected in studies assessing alcohol use through a quantity-
399 frequency approach, in which the respondent reports the frequency of drinking during a specific 
400 time-period and, separately, the typical amount of alcohol consumed on the days that they drank. 
401 This approach may fail to capture variations in drinking around a reported typical quantity, such as 
402 with irregular binge drinking. For example, a person who drinks two drinks daily and a person 
403 who drinks the same amount plus ten additional drinks on Saturday might report the same typical 
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407 Binge drinking has been associated with NAFLD progression in both clinical and mechanistic 
408 studies (Llerena et al., 2015; Ventura-Cots et al., 2017). Binge drinking seems to counteract any 
409 potential benefit from low alcohol use in NAFLD (Mitchell et al., 2018), and the risk associated 
410 with binge drinking seems to arise at binge drinking episodes as infrequently as once monthly 
411 (Åberg et al., 2017; Younossi et al., 2019). Binge drinking emerged as a significant risk factor for 
412 liver disease only among those with the MetS, but not among those without it (Åberg et al., 2017). 
413 It could be speculated that a liver affected by steatosis may lack the capacity of a normal liver to 
414 recover after each episode of drinking during the break from alcohol intake. In support of this, 
415 animal studies show that intermittent alcohol administration serves as a “second hit” by 
416 aggravating hepatic oxidative stress and promoting steatohepatitis and fibrosis in mice with 
417 obesity-induced steatosis (Minato et al., 2014; Duly et al., 2015).
418
419 Low alcohol use in the presence of NAFLD or metabolic risk
420 Although cross-sectional studies report less liver fibrosis among NAFLD subjects with low 
421 alcohol use compared to complete abstinence, the findings are conflicting among studies, the 
422 potential benefit seems to be restricted to wine and non-binge drinking, and, most importantly, 
423 these findings have not been replicated in longitudinal studies. On the contrary, all longitudinal 
424 studies that analyzed specific histological or clinical liver outcomes report a tendency towards 
425 harm to the liver from low alcohol use, without any clear threshold effect.
426
427 A weakness of cross-sectional studies over longitudinal ones is that the predictor and outcome is 
428 measured at the same time, thereby limiting the ability to establish temporal relationship or 
429 causality. On the other hand, many longitudinal studies are unable to determine changes over time 
430 in the level of alcohol intake, or whether subjects develop additional risk factors over time. 
431
432 A good example of the difference between cross-sectional and longitudinal analyzes are the 
433 studies by Dunn et al (Dunn et al., 2012) and Ajmera et al (Ajmera et al., 2018), which were in 
434 part based on the same patient population. Although both studies evaluated lifetime drinking and 
435 made careful efforts to exclude previous drinkers and binge drinkers and adjusted for multiple 
436 confounders, the cross-sectional study by Dunn et al (Dunn et al., 2012) found protective effects of 
437 low alcohol use, whereas the longitudinal study by Ajmera et al (Ajmera et al., 2018) reported 
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439 numerous cross-sectional Japanese studies, the only longitudinal ones reported increased HCC risk 
440 (Kawamura et al., 2016; Kimura et al., 2018).
441
442 Clinic-based studies with liver biopsies often had limited statistical power for multivariate 
443 analyses, whereas many large population studies had limited availability of confounding variables, 
444 thereby risking incomplete adjustment for relevant confounding, especially diet. It is well known 
445 that individuals with low alcohol use tend to exhibit healthier dietary habits, healthier lifestyle, 
446 higher socioeconomic status, and increased physical activity compared to complete abstainers 
447 (Mukamal et al., 2006; Fillmore et al., 1998). These factors are difficult to fully adjust for in 
448 observational studies. Such incomplete adjustment may exaggerate the protective effect of low 
449 alcohol use in NAFLD.
450
451 Many studies adjusted the effect of alcohol for BMI. Alcohol use may cause obesity through 
452 excess calories, and obesity is a risk factor for chronic liver disease. Therefore, some of the effects 
453 of alcohol may be mediated through excess calories and obesity. Adjustment for BMI when 
454 analyzing associations between alcohol and liver disease may hence lead to an over-adjustment 
455 bias, i.e. subjects who consume more alcohol are more likely to gain weight, which in turn 
456 increases their risk of liver disease. This tends to attenuate the observed risks from alcohol.
457
458 Failure to separate lifetime abstainers from current abstainers (previous alcohol use, currently quit 
459 drinking) in many studies also leaves the potential for a sick quitter bias. Current abstainers may 
460 be enriched with former heavy drinkers who present a more severe liver disease that actually 
461 reflect irreversible alcoholic liver disease. Those with more severe liver disease may also be the 
462 ones that choose to quit drinking as a consequence of disease, thereby entering the “non-exposed” 
463 group.
464
465 There is concern for selection bias especially in clinic-based studies (Delgado-Rodriguez and 
466 Llorca, 2004). Considering that the level of alcohol intake is itself involved in the definition of 
467 NAFLD, filtering from clinical decision-making has already taken place when liver disease in a 
468 patient with active alcohol use is categorized as NAFLD; this may result in a distorted spectrum of 
469 baseline disease. Referral criteria of patients to liver clinics, recruitment to clinical studies, and the 
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471 specified. Survey-based general population studies have an advantage in this regard, as they do not 
472 suffer the same selection bias inherent to clinic-based studies.
473
474 Alcohol intake was usually ascertained through the use of questionnaires, or in the clinical setting, 
475 often by physician interviews. Such physician interviews have been shown to be less accurate in 
476 discovering underlying alcohol risk use than cognitive lifetime drinking histories (Hayashi et al., 
477 2004). 
478
479 Both intentional and unintentional underreporting of alcohol use is of major concern. Awareness 
480 of a liver condition may lead to intentional underreporting of alcohol use by the patient in clinical 
481 studies due to a fear that alcohol use will have a negative impact on the care provided. Indeed, 
482 several studies suggest undetected significant alcohol use in many patients with hepatic steatosis 
483 labeled as NAFLD (Hagstrom et al., 2017; Hayashi et al., 2004; Staufer et al., 2019). Again, 
484 prospective population-based studies have an advantage over clinic-based studies, since healthy 
485 participants are more likely to respond honestly, and study subjects are often unaware of having 
486 steatosis when it is defined by specific laboratory indices such as the fatty liver index.
487
488 Unintentional underreporting of alcohol use is also a concern. It is difficult for anyone to 
489 accurately quantify a unit of alcohol, especially as serving size and alcohol content within and 
490 across beverage type may vary considerably. Quantification of alcohol intake typically relies on 
491 recall of past drinking, for instance during the last year, with a significant risk for recall bias 
492 (Stockwell et al., 2004). Underreporting alcohol use tends to increase as risk drinking behaviors 
493 increases, but this is complex and inconsistent (Isted et al., 2015). A general underreporting of 
494 alcohol intake might overestimate the level of alcohol intake needed to induce liver harm, but 
495 underreporting may also be skewed rather than general, whereby the net effect becomes less 
496 predictable.
497
498 Suggestions for future research
499 A key limitation with current longitudinal studies is that alcohol intake is usually assessed only at 
500 one point in time. There is a need for large longitudinal population-based studies that measure 
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503
504 Given that underreporting of alcohol use generally increases together with increasing alcohol use, 
505 and that hazardous alcohol use can contribute to weight gain, potentially there may be more 
506 underreporting of alcohol use in the obese group than in non-obese groups. Therefore, some of the 
507 interaction effect between obesity and hazardous alcohol use could actually represent the effect of 
508 unmeasured alcohol intake. To overcome this uncertainty related to questionnaire-based 
509 ascertainment of alcohol use, there is a need for studies quantifying alcohol intake by sensitive and 
510 specific biomarkers such as phosphatidylethanol (Viel et al., 2012). 
511
512 More study is also needed on how to best incorporate the interaction effects between alcohol and 
513 metabolic risk in clinically useful risk stratification strategies. More data is needed on which 
514 specific obesity-related metabolic components drive these harmful interaction effects for liver 
515 disease. Factors influencing individual susceptibility to alcohol toxicity, including genetics, also 
516 deserve further study.
517
518 It seems that binge drinking is associated with progression of liver disease even when average 
519 alcohol consumption is within the currently allowed limits to receive a NAFLD diagnosis. Binge 
520 drinking probably warrants explicit consideration when designing drug trials in NAFLD, and 
521 should be incorporated in the diagnostic criteria of NAFLD.
522
523 Conclusions
524 Although not entirely consistent, current epidemiologic and clinical evidence point to considerable 
525 supra-additive interaction for the risk of liver disease between hazardous alcohol use and 
526 metabolic abnormalities including obesity, diabetes and the MetS. This merits increased attention 
527 in disease prevention, risk stratification, and individual counseling.
528
529 There is no clear safe limit of alcohol intake in the presence of NAFLD or metabolic risk. The 
530 presence of steatosis seems to amplify alcoholic liver toxicity. Recent studies based on unselected 
531 population cohorts of subjects unaware of having steatosis with longitudinal follow-up for clinical 
532 liver outcomes, and with comprehensive adjustment for confounders, report low alcohol use being 
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534 without advanced liver fibrosis, the absolute risk increase from maximum 1 daily standard glass of 
535 wine (10g of ethanol) seems small.
536
537 Although low alcohol use might ameliorate insulin resistance and thereby possibly reduce hepatic 
538 steatosis, alcohol’s numerous detrimental effects extend well beyond simple fat accumulation, and 
539 the net effect seems to be harmful already at low doses. There is no clinical evidence to support 
540 that low alcohol would protect from symptomatic liver disease. In NAFLD with advanced liver 
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865 FIGURE LEGENDS
866
867 Figure 1. The concept of interaction between alcohol and obesity for the risk of liver disease. 
868 Obesity and metabolic risk may modify the effects on the liver of low alcohol use (<1-3 
869 drinks/day), with some studies reporting harm and other studies reporting benefits from low 
870 alcohol use compared to abstinence. Regarding hazardous alcohol use, studies suggest supra-
871 additive interaction effects between exposure to alcohol (Ralco) and obesity (Robe), so that the 
872 combined risk effect of having both exposures (Rcombi) is higher than the sum of their individual 
873 risk effects (Ralco + Robe).
874
875 Figure 2. Hazards ratios for the contribution of weekly binge drinking, the metabolic syndrome 
876 (MetS), and their combination (interaction) to the risk for incident clinical liver disease in 
877 comparison to subjects without the MetS who reported no binge drinking or binge drinking less 
878 often than once monthly (baseline risk) in the Finnish Health 2000 study. The attributable 
879 proportion due to interaction in this example is 29% ((4.61 – 2.26 – 2.03 + 1) / 4.61 = 0.29). 
880 (Reprinted with permission from Åberg F et al. Binge drinking and the risk for liver events: A 
881 population-based cohort study. Liver International 2017;37:1373 (Åberg et al., 2017).
882
883 Figure 3. Interaction between average alcohol intake (grams of ethanol per week) and waist-hip 
884 ratio for the risk of incident clinical liver disease among men in the Finnish general population. 
885 (Reprinted with permission from Sahlman P et al. Genetic and lifestyle risk factors for advanced 
886 liver disease among men and women. Journal of Gastroenterology and Hepatology 2019 (Sahlman 
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Table 1. Studies analyzing interaction between hazardous alcohol use and obesity for various liver outcomes.
Author, 
year
Country Study design Study subjects Outcome 
measure






Ruhl, 2005 USA Cross-
sectional







Reference: BMI <25 kg/m2 + 
nondrinker   
Drinker: ≥2 drinks/d   
Obese: BMI ≥30 kg/m2
Obese OR 2.1 
Drinker OR 1.6  







Relative differences (%) in mean levels compared to reference group 
ALT: obese +52%  
Drinker +5%  
Obese drinker +105%
- Yes
AST: obese +18%  







2 164 apparently 
health men and 
women recruited 
in a survey to 
establish enzyme 
reference 






Reference: BMI 19-24.9 kg/m2 + 
abstainer   
Drinker: 0-280 g/wk   
Obese: BMI ≥30 kg/m2
GGT: obese +36%  











recruited in 1994 




















Reference: BMI 18.5-24.9 kg/m2 + 
nondrinker   
Drinker: >210 g/wk   
Obese: BMI ≥30 kg/m2
Obese OR 1.4  
Drinker OR 2.1  
Obese drinker OR 8.9











 2 364 men and 
women, mean 







Reference: BMI 18.5-24.9 kg/m2 + 
nondrinker  
Drinker: >210 g/wk   
Obese: BMI ≥30 kg/m2
Obese OR 1.3 
Drinker OR 2.3  
Obese drinker OR 21








Shen, 2010 China Longitudinal 500 men and 
women with 
normal liver 
tests and without 
liver disease 









Reference: BMI <25 kg/m2 + 
alcohol use <280 g/wk   
Drinker: ≥280 g/wk  
Overweight/obese: BMI ≥25 kg/m2
Overweight/obese RR 1.40 
(0.84-2.33)  



























Reference: BMI <25 kg/m2 + 
alcohol use <210 g/wk and lifetime 
alcohol use <100kg   
Drinker: ≥420 g/wk or lifetime use 
≥100kg   
Obese: BMI >30 kg/m2
Obese RR 4.6 (2.5-11.0)  
Drinker RR 2.8 (1.4-7.1)  
Obese drinker RR 5.8 (3.2-
12.3)
- No
MEN Reference: BMI <25 kg/m2 + 
current abstainers   
Drinker: ≥420 g/wk   
Obese: BMI ≥30 kg/m2   
WOMEN Reference: BMI <25 
kg/m2 + current abstainers   
Drinker: >140 g/wk   
Obese: BMI ≥30 kg/m2   
MEN Obese ? (data not 
given)  
Drinker OR 21.5  
Obese drinker OR 101.6   
WOMEN Obese ? (data not 
given)  
Drinker OR 0.15  
Obese drinker HR 3.30
Age, HbA1c Yes ?Lau, 2015 Germany Cross-
sectional
4 009 men and 
women (The 





Reference: BMI <25 kg/m2 + 
nonbinge drinking   
Binge drinker: ≥5 drinks/d ≥1 time 
during the last month   
Obese: BMI ≥30 kg/m2
MEN Obese OR 8.96  
Binge drinker OR 2.73  
Obese binge drinker OR 
14.10   
WOMEN Obese OR 7.31  
Binge drinker OR 1.69  
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2015 sectional women, mean 
age 50 yrs, 
undergoing 
general health 




on US steatosis in obese (BMI >30 
kg/m2) low-drinking (<140 
g/wk) men and obese (BMI 





USA Case-control 70 with HCC 






HCC Reference: BMI <30 kg/m2 + 
alcohol use <100 drinks per lifetime  
Drinker: ≥100 drinks per lifetime 
Obese: BMI ≥30 kg/m2
Obese OR 1.2 (1.4-17.3)  
Drinker OR 2.6 (1.8-7.6)  





Taiwan Longitudinal 2 260 Taiwanese 
hepatitis B-
positive men 




HCC Reference: BMI <30 kg/m2 + 
nondrinker   
Drinker: alcohol use ≥4 d/wk for 
≥1yr  
Obese: BMI ≥30 kg/m2
Obese HR 0.64 (0.16-2.63)  
Drinker HR 1.64 (1.12-
2.40)  








Taiwan Longitudinal 23 712 
Taiwanese 
residents 
HCC Reference: BMI <30 kg/m2 + 
nondrinker   
Drinker: alcohol use ≥4 d/wk for 
Obese HR 1.17 (0.65-2.11)  


























Obese: BMI ≥30 kg/m2











Liu, 2010 England 
and 
Scotland













Reference: BMI 22.5-25 kg/m2 + 
alcohol use <70 g/wk   
Drinker: ≥150 g/wk   
Obese: BMI ≥30 kg/m2
Obese RR 1.35 (1.15-1.59)  
Drinker RR 3.44 (2.70-
4.37)  





















Reference: BMI <25 kg/m2 + 
alcohol use <120 g/wk   
Drinker: ≥120 g/wk   
Overweight/obese: BMI ≥25 kg/m2
Overweight/obese RR 1.29 
(0.60-2.80)  
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alcohol use <9 g/wk   
Drinker: ≥126 g/wk  
Overweight/obese: BMI ≥27.5 
kg/m2 *
Drinker HR 1.3  
Overweight/obese drinker 
HR 3.6 (highest risk in 
underweight drinkers, BMI 





Reference: BMI <25 kg/m2 + 
alcohol use <210g/wk for men and 
<140g/wk  
Drinker: above these sex-specific 
limits   
Obese: BMI >30 kg/m2
Obese HR 1.48  
Drinker HR 5.84  
Obese drinker HR 4.06
Age, sex NoÅberg, 2018 Finland Longitudinal 6 732 men and 
women, mean 














Reference: WC <102 cm + alcohol 
use <210g/wk for men and WC 
<88cm +  alcohol use <140g/wk for 
women  
Drinker: above these sex-specific 
limits   
Obese: WC above these sex-
specific limits
Obese HR 1.46  
Drinker HR 4.55  
Obese drinker HR 6.72
Age, sex Yes 25%
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Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase;OR, odds ratio; GGT, gamma-glutamyltransferase; BMI, body mass 
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Study subjects Outcome 
measure





GGT ≥30 U/L: Metabolic 
syndrome OR 1.79 (1.21-2.66)   
Drinker OR 7.81 (6.07-10.06)   






ALT ≥40 U/L: Metabolic 
syndrome OR ?    
Drinker OR 1.61 (1.00-2.60)    
Metabolic syndrome + drinker 
OR 3.88 (2.00-7.55)










5 946 men and 








Reference: No metabolic 
syndrome + alcohol 
abstainer  
Drinker: ≥24 g/day   
Metabolic syndrome: yes 
(Adult Treatment Panel 
III)
AST ≥40 U/L: Metabolic 
syndrome OR ?    
Drinker OR 3.73 (2.54-5.47)    
Metabolic syndrome + drinker 
OR 6.42 (3.64-11.35)
as above Yes ?
Hassan, 
2002
USA Case-control 115 men and women 
with hepatocellular 





HCC Reference: No diabetes + 
alcohol use <439 g/wk   
Drinker: >439 g/wk   
Diabetes: yes
Diabetes OR 2.4 (1.3-4.5)  
Drinker OR 2.6 (1.4-4.9)  
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USA Case-control 295 men and women 
with hepatocellular 
carcinoma recruited 
in 1984-2002 from a 
population-based 
cancer registry and 
435 matched healthy 
neighboorhood 
control subjects
HCC Reference: No diabetes + 
alcohol use ≤4 drinks/d  
Drinker: >4 drinks/d   
Diabetes: yes
Diabetes OR 2.5 (1.5-4.0)  
Drinker OR 3.4 (2.2-5.4) 
Diabetes + drinker OR 17.3 
(3.9-77.6)






Finland Longitudinal 6 732 men and 
women, mean age 
54 yrs, recruited in 
2000-2001 (Health 








Reference: No diabetes + 
alcohol use <210g/wk for 
men and <140g/wk for 
women  
Drinker: above these sex-
specific limits   
Diabetes: yes
Diabetes HR 2.58  
Drinker HR 3.56  
Diabetes + drinker HR 19.5
Age, sex Yes 74%
Åberg, 
2017
Finland Longitudinal 6 366 men and 
women, mean age 
54 yrs, recruited in 
2000-2001 (Health 








Reference: No metabolic 
syndrome + no binge 
drinking or less than once 
monthly  
Binge drinking: ≥60 
g/occasion at least weekly   
Metabolic syndrome: yes 
(Joint Interim Statement 
Metabolic syndrome HR 2.03 
(1.18-3.47)  
Weekly binge drinking HR 2.26 
(0.76-6.71)   
Metabolic syndrome + weekly 


















USA Longitudinal 4 264 men and 







Reference: No metabolic 
syndrome + alcohol use 
≤3 drinks/day for men or 
≤1.5 drinks/day for 
women  
Drinker: above these sex-
specific limits   
Metabolic syndrome: yes 
(Adult Treatment Panel 
III)
Metabolic syndrome HR 1.32 
(1.04-1.68)  
Drinker HR ?   
Metabolic syndrome + drinker 
3.35 (2.02-5.55)
? Yes ?
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; OR, odds ratio; GGT, gamma-glutamyltransferase; HR, hazards 
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Table 3. Studies analyzing the effects of light-moderate alcohol consumption on steatohepatitis, liver fibrosis, liver cancer or other symptomatic 
advanced liver disease in subjects with baseline fatty liver disease or metabolic risk.
Author, 
year, design









Adjustments Effects of light-moderate 
alcohol use
Dixon 2001,  
Cross-
sectional




History of alcoholism, 
alcohol > 200 g/wk, 
hepatotoxic medication, 
other liver disease
Histology No Excluded Histology DM, IR ↓ NASH (non-significant 
after adjusting for diabetes 
or IR index)
Cotrim 2009,  
Cross-
sectional




Alcohol use > 280 
g/week, other liver 
disease
Histology No n.r. Histology - ↑ insulin sensitivity 
No impact on histology
Ekstedt 2009, 
Longitudinal




Absent follow-up biopsy 
(n=20)
Histology No n.r. Histology Age, sex, BMI, DM, 
weight gain, HOMA-IR, 
fibrosis stage at baseline
Binge drinking  ↑ 
fibrosis progression 
Ascha 2010,  
Cross-
sectional





Other liver disease Histology or 
radiology
No Included HCC Age, sex, race, BMI, 
smoking, DM
Any alcohol use: ↑ HCC 
risk
Dunn 2012,  
Cross-
sectional







Alcohol use >20 g/day, 
monthly binge drinking, 
former drinkers (current 
abstainers) 
Histology Yes Excluded Histology Age, sex, race, income, 
education, BMI, exercise, 
smoking, total calorie 
intake
↓ NASH (OR 0.56)
↓ ballooning (OR 0.66) 
↓ fibrosis (OR 0.56)









Alcohol consumption ≥ 




MRS + US 
elastography
No n.r. MRS + US 
elastography
Age, sex, MetS Weak correlation with liver 
fat content (r=0.11, non-
significant) 





















n.r. Histology No n.r. Histology n.r. ↓ NAFLD and NASH 
↓ liver enzymes and 
inflammatory markers
Kwon 2014,  
Cross-
sectional




History of long-term 
alcohol abuse or 
dependence, or >40 
g/week, other liver 
disease, steatogenic 
medications
Histology Yes Excluded Histology Age, sex, BMI, % body fat, 
HOMA-IR, liver enzymes, 
selected histological 
features
Alcohol use ≥24 gram-









Other liver disease, 
underlying systemic 
disease, follow-up <48 
weeks













Alcohol use > 14 
units/week
Histology Yes n.r. Histology Age, DM, hypertension, 
BMI, smoking
Lifetime alcohol use up to 
13 units/week:  ↓ fibrosis
Kimura 2018,  
Cross-
sectional




n.r. Histology No n.r. HCC Fibrosis, diabetes, 
triglycerides









≥210 g/week (male) or 
≥140 g/week (female), 
other liver diseases, 
steatogenic medications
Histology Yes n.r. Histology Age, sex, DM, BMI, 
HOMA-IR
Alcohol use 1-70 g/wk: ↓ 
advanced fibrosis (OR 
0.33), but only in wine- 





58 927 adults Hospital 
clinic
Alcohol use ≥30 g/day 
for men or ≥20  g/day for 
women, other liver 
disease, steatogenic 
drugs




Age, sex, center, screening 
year, smoking, exercise, 
education, BMI, DM, 
hypertension, dyslipidemia, 
HOMA-IR, hs-CRP




















Alcohol use >3 
drinks/day (men) or >2 
drinks/day (women), 





No n.r. All-cause 
death
Age, sex, smoking , 
ethnicity, exercise, 





≥1.5 drinks/day: ↑ 










Other liver disease, 
steatogenic drugs
US No n.r. All-cause 
death
Age, sex, ethnicity, 
smoking, MetS, 
Alcohol use ≤3 drinks/day 
(men) or ≤1.5 drinks/day 















Alcohol use during 2 
years preceding study of 
>20 g/day (men) or >10 
g/day (women), or ≥6 
drinks/occasion, other 
liver disease
Histology Yes Excluded Histology Age, sex, ethnicity, 
smoking 
Less reduction over time in 
steatosis grade













Alcohol use >50g/day, 
past drinkers (current 
abstainers), baseline 












Age, sex, BMI, smoking, 
exercise, DM, marital 
status, education, 
employment
↑ liver-related morbidity 




J-shaped association with 
all-cause death among 
never smokers
Abbreviations: DM, diabetes mellitus; IR, insulin resistance; NASH, non-alcoholic steatohepatitis; NAFLD, non-alcoholic fatty liver disease; BMI, 
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spectroscopy; US, ultrasound; MetS, metabolic syndrome; AST, aspartate aminotransferase; GGT, gamma-glutamyltransferase; NFS, NAFLD 















Supra-additive interaction: Rcombi >> Robe + Ralco
Attributable proportion (%) due to interaction = 
Rcombi






















































Excess risk due to interaction
Excess risk due to weekly binging
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